Compare Standard Lithium Ltd (SLI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? Standard Lithium Ltd trades at $1.41 (market cap $354.24M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 13.8× Standard Lithium Ltd's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 24 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SLI | TVTX | |
|---|---|---|
Market Cap | $354.24M | $4.88B |
Volume | 1,656,773 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $67.52 |
52-Week Low | $1.38 | $26.79 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $217.16M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.43, down 4.03% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no current revenue, but has made significant progress on its Arkansas lithium project with recent offtake agreements and government support. Analyst consensus remains strongly bullish with 100% buy ratings and a $3.83 price target, representing 168% upside potential from current levels.
The investment case hinges on successful execution of the South West Arkansas project, which could begin production in 2029. Key risks include negative cash flow from operations, high capital requirements, and project timeline delays. The stock offers speculative upside if the company can transition from development to production phase successfully.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
